UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated its Buy rating on Danaher with a $260 price target versus a $231.13 share price, saying the company met four monitored objectives. Third-quarter core revenue grew 2.5%–3.0% year over year, and Danaher maintained its fourth-quarter non-flu guidance while taking steps to reduce risk around 2027 expectations. Separately, reported Q3 2026 adjusted EPS of $2.11 and revenue of $6.6 billion beat forecasts, although shares fell in premarket trading amid respiratory-revenue concerns.

Analysis

The important signal is the market’s response to the beat: investors appear to be discounting forward earnings quality, not rewarding the quarter’s headline delivery. If respiratory weakness persists, stronger nonrespiratory demand may not fully offset mix or operating-leverage pressure; the key test is whether broad-based core growth improves, rather than whether one quarter clears estimates. UBS’s “clearing event” framing may help reset expectations for 2027, but it is an analyst interpretation, not evidence that uncertainty has passed.

After a strong six-month run and with the shares near their recent high, incremental upside depends increasingly on follow-through. A new CEO adds potential strategic upside over 6–18 months, but also raises execution and guidance-credibility risk. The cited fair-value estimate is not a reliable standalone valuation anchor; verify valuation against current earnings estimates and peer multiples. Thermo Fisher (TMO) is a relevant relative-performance benchmark, but the supplied information does not establish a valuation or fundamentals advantage for either company.

Key Decisions for Investors

• Avoid chasing DHR solely on the earnings beat or analyst target increases. Prefer waiting for a pullback or evidence that core growth is broadening and respiratory trends are stabilizing.
• Over the next 1–3 months, track respiratory revenue commentary, nonrespiratory growth, and any change in full-year or 2027 expectations. A further deterioration in respiratory trends or a downward guidance revision would falsify the improving-outlook thesis.
• For relative-value investors, place DHR versus TMO on watch rather than initiating a pair trade now. Consider an underweight in DHR only if updated peer valuation and estimates show its rerating has outpaced fundamentals; reassess if DHR delivers sustained broad-based growth.
• Treat the CEO transition as a 6–18 month catalyst, not an immediate earnings driver. Look for strategy and execution evidence in guidance and operating results before assigning it a valuation premium.